Additional disclosure concerning Michael Owen

RNS Number : 0933H

Sareum Holdings PLC

29 July 2019

 

(AIM: SAR)

29 July 2019

Sareum Holdings plc

("Sareum" or "the Company")

Additional disclosure concerning Michael Owen

Sareum Holdings PLC, the specialist small molecule drug development business, announced on 13 November 2018 the appointment of Michael Owen as a Non-Executive Director of the Company.

It has come to Sareum's attention that whilst his former directorship of BliNK Biomedical SAS ("BliNK") was detailed in that announcement, his former directorship of BliNK's subsidiary Blink Therapeutics Limited during the five years prior to that announcement should also have been included.

For further information, please contact: 

Sareum Holdings plc
Tim Mitchell	01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford	020 7220 1666
Hybridan LLP (Nominated Broker)
Claire Noyce	020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David Dible	020 7638 9571

- Ends -

 

END

 

 

RDNEKLFLKDFLBBQ